Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion {equilateral_black_triangle}

Active Ingredient:
blinatumomab
Company:  
Amgen Ltd See contact details
ATC code: 
L01FX07
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

BLINCYTO®▼ (blinatumomab) – Clarification of timing of premedication with dexamethasone in paediatric patients

{healthcare_pro_orange} For Healthcare Professionals
A potentially confusing statement which led to a translation issue has been discovered in the Blincyto® Summary of Product Characteristic (SmPC) Section 4.2 regarding the second administration of dexamethasone as premedication in paediatric patients

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Amgen Ltd
Company image
Address
216 Cambridge Science Park, Milton Road, Cambridge, CB4 0WA, UK
Telephone
+44 (0)1223 420 305
Fax
+44 (0)1223 426 314
Customer Care direct line
+44 (0)808 0100 321
Medical Information Direct Line
+44 (0)1223 436 441
Medical Information e-mail
[email protected]
Medical Information Fax
+44 (0)1223 426 314